Celecoxib and Radiation Therapy for Prostate Cancer
Author Information
Author(s): Ganswindt U, Budach W, Jendrossek V, Becker G, Bamberg M, Belka C
Primary Institution: University of Tübingen
Hypothesis
Does the combination of celecoxib and percutaneous radiation therapy increase toxicity in prostate cancer patients?
Conclusion
The combination of irradiation to the prostate with concurrent high dose celecoxib was not associated with an increased level of side effects.
Supporting Evidence
- No grade 3 or 4 toxicity was observed in the study.
- 85% of patients experienced grade 1 gastrointestinal toxicity.
- 80% of patients experienced grade 1 genitourinary toxicity.
Takeaway
Doctors wanted to see if a medicine called celecoxib could be safely used with radiation therapy for prostate cancer without causing more side effects. They found it was safe.
Methodology
22 patients received 400 mg of celecoxib twice daily during radiation therapy, with toxicity assessed weekly and at follow-ups.
Potential Biases
Potential bias due to the open-label design and lack of control group.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
{"median_age":67,"age_range":"49-74","initial_PSA_range":"2.4-18.3 ng/ml","hormonal_ablation":{"yes":14,"no":6}}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website